GlassScriptPhysician profile
Mckenzie Martin
NPI 1144088048
$1,512.41
in general payments reported to CMS, 2019-2025
21 companies · $987 in 2025
The $987 reported for 2025 was more than what 85% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $526 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.58 |
| Education | $364.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $273.22 | 2025 | Carvykti |
| Janssen Biotech, INC. | $181.29 | 2024-2025 | Rybrevant, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $154.19 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.12 | 2024-2025 | Lynparza, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $139.60 | 2024 | Reblozyl |
| Pharmacosmos Therapeutics INC. | $118.89 | 2025 | Monoferric |
| Genzyme Corporation | $89.56 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.54 | 2025 | Ninlaro, Iclusig |
| Genentech USA, INC. | $39.54 | 2025 | Itovebi, Tecentriq |
| Merck Sharp & Dohme LLC | $37.20 | 2024-2025 | Lynparza, Keytruda |
| Sobi, INC | $35.43 | 2024-2025 | |
| Lilly USA, LLC | $35.03 | 2025 | Jaypirca, Verzenio |
| Alexion Pharmaceuticals, INC. | $34.49 | 2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $26.25 | 2025 | Libtayo |
| Kerecis Limited | $24.49 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $22.13 | 2025 | |
| Puma Biotechnology, INC. | $22.00 | 2024 | |
| Myriad Genetic Laboratories, INC. | $21.08 | 2025 | Prolaris |
| Abbvie INC. | $19.39 | 2024 | |
| Gilead Sciences, INC. | $18.97 | 2024 | |
| Celgene Corporation | $16.00 | 2025 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mckenzie Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.